SECTION 2 - 510(k) SUMMARY

EXOJET Tissue Management System

Submitter's Name and Address:

Mitek Worldwide

a division of ETHICON Inc.

a Johnson & Johnson Company

249 Vanderbilt Avenue Norwood, MA 02062

Contact Person

Sergio J. Gadaleta, Ph.D.

Manager, Regulatory Affairs

Mitek Worldwide

a division of ETHICON Inc. a Johnson & Johnson Company

249 Vanderbilt Avenue Norwood, MA 02062

Telephone:

781-251-2018

Facsimile:

781-278-9578

e-mail:

sgadalet@ethus.jnj.com

Name of Medical Device

Classification Name:

Arthroscope and Accessories

Common/Usual Name:

Arthroscope and Accessories

Proprietary Name:

EXOJET Tissue Management

Substantial Equivalence

EXOIET Tissue Management System is substantially equivalent to:

Hydrocision ARTHROJET System with Cautery and TurboBurr K020688, K002764, K993009, K982266 – Distributed by Mitek Worldwide a division of Ethicon, Inc., a Johnson & Johnson Company, 249 Vanderbilt Avenue, Norwood, MA 02062 and manufactured by Hydrocision Inc., 100 Burtt Road G01, Andover,

MA 01810.

Device Classification

Arthroscopes and accessories are classified by FDA as a Class II Medical Devices under the generic category of Arthroscope (reference 21 CFR §888.1100), product code HRX.

Device Description

Mitek's EXOJET Tissue Management System consists of reusable power control unit; sterile, disposable pump cartridge and tubing assembly, and sterile, disposable handpieces. It provides the same functions as the predicate device including cutting, evacuation, and electrocauterization. The various handpieces are designed to provide the additional functions of cutting, drilling, reaming, decorticating, and smoothing of bone The handpiece includes a rotating burr, which is driven by a liquid-jet driven motor. It is also available with a variety of burrs and drills.

Indications for Use

The Mitek EXOJET* system is indicated for orthopedic surgical procedures where the cutting and removal of soft tissue, hard tissue, or bone is required, with control of bleeding during those procedures as needed. Specific functions include cutting, ablation, and shaping of soft tissue, and decorticating, removing, and smoothing of bone and other bone-related tissue in a variety of small and large joint arthroscopic procedures.

Safety

Biocompatibility studies have demonstrated the EXOJET Tissue Management System to be non-toxic, non-irritating, non-sensitizing, and non-cytotoxic.



MAY 3 0 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Sergio J. Gadaleta, Ph.D. Manager, Regulatory Affairs Mitek Worldwide a division of Ethicon, Inc. 249 Vanderbilt Avenue Norwood, Massachusetts 02062

Re: K031406

Trade/Device Name: EXOJET Tissue Management System

Regulation Number: 21 CFR 888.1100

Regulation Name: Arthroscope

Regulatory Class: II Product Code: HRX Dated: May 2, 2003 Received: May 20, 2003

Dear Dr. Gadaleta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

Device Name: EXOJET Tissue Management System
Indications for Use:
The Mitek EXOJET* system is indicated for orthopedic surgical procedures where the cutting and removal of soft tissue, hard tissue, or bone is required, with control of bleeding during those procedures as needed. Specific functions include cutting, ablation, and shaping of soft tissue, and decorticating, removing, and smoothing of bone and other bone-related tissue in a variety of small and large joint arthroscopic procedures.
(Division Sign-Off) Division of General, Restorative and Neurological Devices 510(k) Number K03/406
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use or Over-the-Counter Use

510(k) Number (if known): <u>K03140(</u>